FDA Grants Priority Review to Viridian Therapeutics' Veligrotug for Thyroid Eye Disease
I'm PortAI, I can summarize articles.
Viridian Therapeutics announced that the FDA has accepted the Biologics License Application for veligrotug, a treatment for thyroid eye disease, granting it Priority Review. This shortens the review period to six months, with a target action date of June 30, 2026. The application is supported by positive phase 3 trial results, and preparations for commercial launch are underway. A similar application to the European Medicines Agency is planned for early 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments